SCANCELL (LSE:SCLP)

 

SCANCELL (SCLP.L, LSE, LSE:SCLP)

SCLP Share PerformanceMore

52 week high40.490 30/10/14
52 week low22.555 31/03/15
52 week change -10.125 (-29.56%)
4 week volume7,636,098 06/03/15

Media for (SCLP)

Presenter: Dr Richard Goodfellow
24/03/2015
Presenter: Mike Mitchell, Director, Equity Research
11/12/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Second Price Monitoring Extn

RNS Number: 3540I Scancell Holdings Plc 24 March 2015 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The closing auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-determ...

Price Monitoring Extension

RNS Number: 3520I Scancell Holdings Plc 24 March 2015 Price Monitoring Extension Today's closing auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's closing auction call be...

SCIB2 synergy with checkpoint inhibitor blockade

RNS Number: 2476I Scancell Holdings Plc 24 March 2015 24 March 2015 Scancell Holdings Plc SCIB2 also shown to synergise with checkpoint inhibitor blockade Combining SCIB2 with CTLA-4 blockade enhances tumour destruction and extends survival times Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatme...

SCIB2 also shown to synergise with checkpoint inhibitor blockade

Positive SCIB1 Phase 1/2 clinical trial update

RNS Number: 8434B Scancell Holdings Plc 12 January 2015 12 January 2015 Scancell Holdings Plc Scancell to provide positive SCIB1 Phase 1/2 clinical trial update during corporate presentations 12-15 January, San Francisco Part 2 patients have median survival time of 28 months since study entry All resected patients are still alive with median survival time of 30 mont...

Holding(s) in Company

RNS Number: 8294Z Scancell Holdings Plc 15 December 2014 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Scancell Holdings plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An...

Scancell Holdings - Analyst Interview, Panmure Gordon

Half Yearly Report

RNS Number: 3125Z Scancell Holdings Plc 10 December 2014 10 December 2014 Scancell Holdings Plc Interim Results for the six months ended 31 October 2014 SCIB1 continues to generate highly encouraging survival data; Modi-1 vaccine on track for 2016 entry into clinic Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for th...